David Spellman

Geen lopende functies

Vermogen: - $ op 30-04-2024

48 jaar

Health Technology

Consumer Services

Eerdere bekende functies van David Spellman

Bedrijven	Functie	Begin	Einde
AKEBIA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	30-12-2022	23-06-2023
	Financieel Directeur/CFO	29-06-2020	23-06-2023
	Treasurer	29-06-2020	23-06-2023
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Financieel Directeur/CFO	01-11-2019	29-06-2020
	Corporate Officer/Principal	01-06-2019	01-11-2019
MERSANA THERAPEUTICS, INC.	Financieel Directeur/CFO	12-03-2018	30-06-2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	-	-

The Wharton School of the University of Pennsylvania

Undergraduate Degree

Internationaal

Verenigde Staten

Operationeel

Director of Finance/CFO	3
Corporate Officer/Principal	2
Undergraduate Degree	1

Sectoraal

Health Technology	5
Consumer Services	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	3
MERSANA THERAPEUTICS, INC.	Health Technology
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology
AKEBIA THERAPEUTICS, INC.	Health Technology

Bedrijven in privébezit	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology

Bedrijven in privébezit

Health Technology